Short Disease Duration Does Not Always Indicate Early Crohn’s Disease

医学 维多利祖马布 克罗恩病 坏疽性脓皮病 疾病 炎症性肠病 溃疡性结肠炎 内科学 胃肠病学
作者
Iago Rodríguez‐Lago,Manuel Barreiro‐de Acosta
出处
期刊:Clinical Gastroenterology and Hepatology [Elsevier BV]
卷期号:17 (8): 1646-1646 被引量:2
标识
DOI:10.1016/j.cgh.2019.01.017
摘要

We read with interest the article recently published by Faleck et al,1Faleck D.M. et al.Clin Gastroenterol Hepatol. 2019; https://doi.org/10.1016/j.cgh.2018.12.040Abstract Full Text Full Text PDF Scopus (32) Google Scholar in which they reported the results of a subanalysis performed within the US Vedolizumab for Health Outcomes in Inflammatory Bowel Diseases (VICTORY) Consortium. The investigators observed that the early use of vedolizumab (<2 years since the diagnosis) in patients with Crohn's disease was associated with higher rates of clinical remission, steroid-free clinical remission, and mucosal healing. Although we believe that these results provide relevant information for our clinical practice, it is necessary to highlight some aspects when interpreting the data, especially when evaluating the possible relationship between the time since the diagnosis of Crohn’s disease and its severity. The group of patients with a shorter disease duration was composed of 62 patients in whom 39% showed a stenosing or penetrating behavior, 23% had fistulas, and 35% had already undergone surgery. In addition, 60% of the cases already had shown an inadequate response to anti–tumor necrosis factor biologics, with up to 34% of subjects who had been exposed to at least 2 of these drugs. These results are in line with findings from European centers, in which up to 39% of patients showed advanced intestinal lesions shortly after diagnosis.2Fiorino G. et al.J Crohns Colitis. 2017; 11: 274-280Crossref PubMed Google Scholar The relevance of these data comes from the association of bowel damage with a higher rate of hospitalization and surgery during follow-up evaluation. Regarding the treatment strategy in Crohn’s disease, we strongly believe that early therapy undoubtedly will benefit an important number of patients by preventing the progression of the inflammatory process toward more aggressive and complicated forms of the disease. For this reason, we consider it of great importance to extend our research on these early stages of the disease because, despite a short period of time since the diagnosis, it is possible that this group of patients represents an early and severe disease phenotype. Moreover, some factors, such as the time since the onset of the first symptoms or even a possible delay in the establishment of a definite diagnosis, may influence our findings.3Schoepfer A. et al.J Crohns Colitis. 2015; 9: 597-598Crossref PubMed Scopus (4) Google Scholar The inclusion of patients who already have developed complications (stenosis or fistulas) or who previously had undergone surgery limits our capacity to draw conclusions about the disease-modifying effect of current therapeutic options on the natural history of Crohn’s disease. Despite being considered early, the characteristics of the cohort of patients analyzed by Faleck et al1Faleck D.M. et al.Clin Gastroenterol Hepatol. 2019; https://doi.org/10.1016/j.cgh.2018.12.040Abstract Full Text Full Text PDF Scopus (32) Google Scholar included a significant proportion of subjects (at least 60%) who will not fulfill the early Crohn’s disease criteria as defined by the Paris definition.4Peyrin-Biroulet L. et al.Am J Gastroenterol. 2012; 107: 1770-1776Crossref PubMed Scopus (82) Google Scholar We have observed an increase in the number of studies (both in clinical trials and observational studies) that assessed the efficacy of multiple drugs in the early phases of Crohn’s disease, but the heterogeneity of the criteria used to define early disease limits our capacity to obtain strong conclusions in this field. Although we received the present results reported by Faleck et al1Faleck D.M. et al.Clin Gastroenterol Hepatol. 2019; https://doi.org/10.1016/j.cgh.2018.12.040Abstract Full Text Full Text PDF Scopus (32) Google Scholar with great interest, we believe that future studies should take these aspects into account to obtain robust data on early disease control, prevention of intestinal damage, and how to control the progression of the disease from its early stages. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative ColitisClinical Gastroenterology and HepatologyVol. 17Issue 12PreviewPatients with Crohn’s disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration. Full-Text PDF Open AccessReplyClinical Gastroenterology and HepatologyVol. 17Issue 8PreviewWe thank Drs Rodriguez-Lago and Acosta for their interest in our study and appreciate their comments regarding early Crohn’s disease (CD). We agree that there is a definite need for better definitions and criteria for early CD because the current definition is based on expert consensus. We chose the 2-year cutoff for defining early CD because most post hoc analyses of tumor necrosis factor antagonist clinical trials have used this definition when examining differences in response rates by disease duration. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
筱筱完成签到 ,获得积分10
2秒前
蜀山刀客完成签到,获得积分10
2秒前
无心的千雁完成签到,获得积分10
2秒前
英语小A完成签到,获得积分10
2秒前
dajiejie完成签到 ,获得积分10
2秒前
HelloFM完成签到,获得积分10
3秒前
Super完成签到,获得积分10
4秒前
5秒前
标致思枫完成签到,获得积分10
5秒前
Vv发布了新的文献求助10
5秒前
5秒前
5秒前
马伯乐完成签到 ,获得积分10
7秒前
weijinfen完成签到,获得积分10
7秒前
小灯完成签到,获得积分10
8秒前
Heaven完成签到 ,获得积分10
10秒前
饱满服饰发布了新的文献求助10
11秒前
hh会辉煌发布了新的文献求助10
12秒前
CipherSage应助灵巧的黑子采纳,获得10
14秒前
小黄完成签到 ,获得积分10
15秒前
金石为开完成签到,获得积分10
17秒前
csg888888完成签到,获得积分10
18秒前
水波不兴完成签到 ,获得积分10
18秒前
damaye完成签到,获得积分10
19秒前
20秒前
22秒前
李爱国应助ENEN采纳,获得10
22秒前
23秒前
田様应助wowser采纳,获得10
24秒前
zzz627发布了新的文献求助10
25秒前
PPSlu完成签到,获得积分10
25秒前
LZJ完成签到 ,获得积分10
26秒前
嬛嬛完成签到,获得积分10
26秒前
迅速的大山完成签到 ,获得积分10
27秒前
28秒前
29秒前
ding7862完成签到,获得积分10
30秒前
leo完成签到,获得积分10
31秒前
静心求真金教授完成签到,获得积分10
33秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Molecular Mechanisms of Photosynthesis, 4th Edition 1000
Organic Reactions, Volume 116 1000
Matrix Methods in Data Mining and Pattern Recognition 510
Social Skills Improvement System-Rating Scales--Chinese Version 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7252936
求助须知:如何正确求助?哪些是违规求助? 8875073
关于积分的说明 18734672
捐赠科研通 6933528
什么是DOI,文献DOI怎么找? 3199831
关于科研通互助平台的介绍 2374606
邀请新用户注册赠送积分活动 2174506